Table 2.

Characteristics of the study population (n = 13)

Gender	Age, years	Underlying condition	Functional classification	Pathophysiological classification	Clinical classification	HPN/HPH	Initial BMI	Final BMI	Outcome
Male	71	Colorectal cancer	Type III	Short bowel	D2	HPN	14.7	18.4	Deceased
Female	84	Intestinal ischemia	Type III	Short bowel	D2	HPN	20.0	26.7	Deceased
Male	65	Crohn's disease	Type II	Short bowel + intestinal fistula	D3	HPN	17.7	20.1	Alive without IVS
Male	68	Colorectal cancer	Type III	Short bowel	A2	HPH	26.2	27.5	Deceased
Male	69	Familial adenomatous polyposis	Type III	Short bowel	A2	HPH	16.4	27.9	Alive without IVS
Female	58	Malabsorption from rituximab	Type III	Extensive bowel mucosal disease	D2	HPN	16.0	22.9	Deceased
Female	63	Bowel adhesions	Type III	Short bowel + obstruction	A2	HPH	25.3	28.8	Alive with IVS
Female	92	Umbilical hernia	Type III	Short bowel	D2	HPN	18.1	21.6	Deceased
Female	83	Hernioplasty prosthesis fistula	Type II	Intestinal fistula	D3	HPN	24.6	29.6	Alive without IVS
Female	62	Intestinal dysmotility	Type III	Intestinal dysmotility	D3	HPN	16.5	19	Alive without IVS
Male	28	Crohn's disease	Type III	Short bowel	D3	HPN	14.7	19.7	Alive with IVS
Female	46	Gynecological cancer surgery	Type III	Short bowel	D3	HPN	15.3	21.8	Alive with IVS
Male	36	Familial adenomatous polyposis	Type III	Short bowel	A2	HPH	20.5	21.9	Alive with IVS

HPN, home parenteral nutrition; HPH, home parenteral hydration; BMI, body mass index; IVS, intravenous supplementation.